However, additional findings indicate the necessity of targeting multiple coinhibitory ICPs rather than targeting TIM-3 alone to maximize therapeutic efficacy in the context of AML and solid tumors in mice [131, 137]. Here, HAVCR2 is linked to acute myeloid leukemia.